Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carcinoma, Squamous Cell
/ drug therapy
Cetuximab
/ therapeutic use
Head and Neck Neoplasms
/ drug therapy
Humans
Neoplasm Recurrence, Local
/ drug therapy
Paclitaxel
/ therapeutic use
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Head and neck squamous cell carcinoma
cetuximab
metastasis
paclitaxel
recurrent
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
06
05
2020
revised:
19
05
2020
accepted:
20
05
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Head and neck cancers account for 8% of all cancer cases worldwide. However, identifying the optimal treatment for recurrent or metastatic head and neck cancer (R/MHNSCC) has been challenging. The aim of this study was to evaluate the efficacy, safety, and prognostic factors of the outcome of patients with R/MHNSCC who were treated with weekly cetuximab and paclitaxel (Cmab-PTX). The records of R/MHNSCC patients who were treated with Cmab-PTX in our institution between June 2013 and September 2017 were collected. We analyzed Overall survival (OS), progression-free survival (PFS), prognostic factors and adverse events. The records of 59 patients treated with Cmab-PTX were analyzed. The median PFS was 5.7 months, and the median OS was 11.8 months. Patients who had been administered cetuximab previously had shorter PFS and OS than those who had not. Cmab-PTX may be considered as a treatment option in head and neck R/MHNSCC patients.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Head and neck cancers account for 8% of all cancer cases worldwide. However, identifying the optimal treatment for recurrent or metastatic head and neck cancer (R/MHNSCC) has been challenging. The aim of this study was to evaluate the efficacy, safety, and prognostic factors of the outcome of patients with R/MHNSCC who were treated with weekly cetuximab and paclitaxel (Cmab-PTX).
PATIENTS AND METHODS
METHODS
The records of R/MHNSCC patients who were treated with Cmab-PTX in our institution between June 2013 and September 2017 were collected. We analyzed Overall survival (OS), progression-free survival (PFS), prognostic factors and adverse events.
RESULTS
RESULTS
The records of 59 patients treated with Cmab-PTX were analyzed. The median PFS was 5.7 months, and the median OS was 11.8 months. Patients who had been administered cetuximab previously had shorter PFS and OS than those who had not.
CONCLUSION
CONCLUSIONS
Cmab-PTX may be considered as a treatment option in head and neck R/MHNSCC patients.
Identifiants
pubmed: 32871796
pii: 34/5/2653
doi: 10.21873/invivo.12084
pmc: PMC7652519
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2653-2657Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Oral Oncol. 2017 Oct;73:21-26
pubmed: 28939072
Front Oncol. 2019 Aug 21;9:668
pubmed: 31497530
Eur Arch Otorhinolaryngol. 2014 Feb;271(2):373-8
pubmed: 23644939
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
South Asian J Cancer. 2017 Jan-Mar;6(1):11-14
pubmed: 28413788
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Laryngoscope. 2017 Jul;127(7):1583-1588
pubmed: 27905113
Clin Transl Oncol. 2017 Jun;19(6):769-776
pubmed: 28120324
Anticancer Drugs. 2012 Oct;23(9):996-1001
pubmed: 22643048
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Front Oncol. 2018 Dec 13;8:616
pubmed: 30619755
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Oral Oncol. 2013 Feb;49(2):182-5
pubmed: 23026069
Ann Oncol. 2012 Apr;23(4):1016-22
pubmed: 21865152
Front Oncol. 2017 May 09;7:72
pubmed: 28536670